Tirzepatide
Dual GLP-1/GIP Agonist
The compound behind Mounjaro/Zepbound. Dual GLP-1 and GIP receptor agonist producing dramatic fat loss, appetite suppression, and metabolic improvements beyond semaglutide alone.
Starting From
$149.99
Sold By
Apollo Peptide Sciences
Suggested Protocol
Dose escalation: 2.5mg weekly for 4 weeks, then 5mg for 4 weeks, then 7.5mg, 10mg, 12.5mg, and 15mg at 4-week intervals. Slower escalation reduces GI side effects. Maintenance at 10–15mg weekly. SubQ injection once weekly.
22.5%
Body Wt. Loss
2 (Dual)
Receptors
Once weekly
Dosing
Why Adding the Second Receptor Changed Everything About Weight Loss Pharmacology
Tirzepatide — marketed as Mounjaro for diabetes and Zepbound for weight loss — represents the next evolution in GLP-1-based fat loss compounds. While semaglutide activates only the GLP-1 receptor, tirzepatide is a "twincretin" that simultaneously activates both GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) receptors, producing superior fat loss outcomes through dual receptor engagement.
The GIP receptor activation provides additive and potentially synergistic mechanisms beyond GLP-1 alone: improved insulin secretion (glucose-dependent), enhanced fat storage inhibition at adipose tissue, and potentially improved tolerability compared to pure GLP-1 agonism. The combination produces fat loss effects that significantly exceed semaglutide in head-to-head comparisons.
The SURMOUNT-1 trial — the pivotal tirzepatide weight loss study — demonstrated an average body weight reduction of 22.5% at the highest dose (15mg weekly), representing the highest fat loss efficacy ever documented for any pharmaceutical compound in a large clinical trial until retatrutide emerged. At the 5mg dose, average weight reduction was 15% — already exceeding semaglutide's maximum efficacy.
Beyond weight loss, tirzepatide produces dramatic metabolic improvements: HbA1c reductions of 2.1–2.4%, significant reductions in triglycerides and LDL cholesterol, and blood pressure improvements that make it one of the most comprehensively metabolically beneficial compounds in research.
Available from Apollo Peptide Sciences in 15mg vials.
What GIP Adds
The Glucose-Dependent Insulinotropic Polypeptide Effect — Why It Made Tirzepatide Better Than Semaglutide
GIP (Glucose-dependent Insulinotropic Polypeptide) was initially thought to be lipogenic — a concern that made researchers skeptical about adding GIP agonism to a weight loss compound. Tirzepatide's Phase 3 data reversed that assumption entirely. GIP receptor activation in the context of GLP-1 co-agonism appears to enhance fat storage inhibition in adipose tissue, improve insulin sensitivity through a different pathway than GLP-1, and — critically — improve GI tolerability compared to pure GLP-1 agonism. The GIP component is what allowed tirzepatide to produce dramatically superior fat loss to semaglutide with comparable or better tolerability.
The SURMOUNT-1 Numbers
22.5% Body Weight Reduction: What That Actually Looks Like and What the Data Shows
22.5% average body weight reduction at 72 weeks sounds like a percentage — but in practical terms, for a 220-pound person that's roughly 50 pounds of body weight loss. This was the highest fat loss efficacy ever documented in a large pharmaceutical clinical trial until retatrutide's Phase 2 data. Even at the lowest tested dose (5mg weekly), tirzepatide averaged 15% weight reduction — already exceeding semaglutide's maximum. The dose-response relationship is clear: more tirzepatide means more fat loss, up to the 15mg ceiling tested in SURMOUNT-1, with the metabolic improvements (HbA1c, triglycerides, blood pressure) scaling proportionally.
Mounjaro vs. Research Tirzepatide
Same Molecule, Different Format — What You Need to Know About How Tirzepatide Is Supplied
Mounjaro and Zepbound contain tirzepatide — the identical compound supplied by Apollo Peptide Sciences in lyophilized research format. The pharmaceutical versions come in pre-filled pens at fixed dose increments, auto-injectors, and with the full pharmaceutical supply chain markup. Apollo's tirzepatide gives researchers access to the same active compound in a reconstitutable vial format, at a substantially lower cost per milligram, with full flexibility over concentration, dose, and protocol structure. The pharmacology is the same; the format and price point are different.
Key Benefits
Up to 22.5% body weight reduction demonstrated in clinical research
Dual GLP-1/GIP receptor activation for superior fat loss vs. semaglutide alone
Significant improvement in insulin sensitivity and glucose metabolism
Reduces triglycerides and improves lipid profiles comprehensively
Powerful, sustained appetite suppression through dual receptor pathways
May have better GI tolerability than pure GLP-1 agonists due to GIP activation
Available in multiple formats including 4-pack and 10-pack bulk options
Weekly subcutaneous injection protocol — minimal administration burden
Full Protocol
Dose escalation: 2.5mg weekly for 4 weeks, then 5mg for 4 weeks, then 7.5mg, 10mg, 12.5mg, and 15mg at 4-week intervals. Slower escalation reduces GI side effects. Maintenance at 10–15mg weekly. SubQ injection once weekly.
More in Weight Management
View All
Semaglutide
The compound behind Ozempic/Wegovy. GLP-1 receptor agonist producing significant appetite suppression, fat loss, and metabolic improvement with once-weekly dosing.
